Osteoporosis in men: An Endocrine Society clinical practice guideline

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 6, 2012, Pages 1802-1822

  Watts, Nelson B ^a   Adler, Robert A ^b   Bilezikian, John P ^c   Drake, Matthew T ^d   Eastell, Richard ^e   Orwoll, Eric S ^f   Finkelstein, Joel S ^g  

^a Mercy Health Osteoporosis and Bone Health Services   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTRADIOL; GLUCOCORTICOID; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; SEX HORMONE; TESTOSTERONE; TESTOSTERONE ENANTATE; TOREMIFENE; ZOLEDRONIC ACID;

ANDROGEN THERAPY; BONE DENSITY; CALCIUM INTAKE; CLINICAL EVALUATION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRADIOL BLOOD LEVEL; EVIDENCE BASED PRACTICE; HUMAN; HYPOGONADISM; INCIDENCE; LIFESTYLE; MALE; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PATHOGENESIS; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

AGED; CONSENSUS; ENDOCRINOLOGY; EVIDENCE-BASED MEDICINE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; RISK FACTORS;

EID: 84861973260     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-3045     Document Type: Review

References (203)

1. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer TT, Varonen H, Vist GE, Williams Jr JW, Zaza S 2004 Grading quality of evidence and strength of recommendations. BMJ 328:1490
2. Swiglo BA, Murad MH, Schünemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM 2008 A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 93:666-673 (Pubitemid 351398536)
3. Murad MH, Mullan R, Drake M, Mauck K, Lane MA, Stuart L, Abo Alnour N, Hazem A, Li T, Puhan M, Erwin PJ, Montori VM 2012 Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97:1861-1870
4. Drake M, Murad MH, Lane MA, Mullan R, Mauck K, Stuart L, Hazem A, Undavalli C, Berima T, Prasad C, Erwin PJ, Montori VM 30 March 2012 Risk factors of osteoporosis related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab doi: 10.1210/jc.2011-3058
5. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy 2001 Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795
6. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson AN 2007 Incidence and economic burden of osteoporosis- related fractures in the United States. J Bone Miner Res 22:465-475 (Pubitemid 46797130)
7. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR 2009 Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301: 513-521
8. Forsén L, Sogaard AJ, Meyer HE, Edna T, Kopjar B 1999 Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int 10:73-78 (Pubitemid 29428018)
9. Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S 2010 Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380-390
10. Amin S 2010 Epidemiology of fractures. In: Orwoll ES, Bilezikian JP, Vanderschueren D, eds. Osteoporosis in men. San Diego: Academic Press; 351-360
11. Kanis JA, Pitt FA 1992 Epidemiology of osteoporosis. Bone 13(Suppl 1):S7-S15
12. Singer BR, McLauchlan GJ, Robinson CM, Christie J 1998 Epidemiology of fractures in 15,000: the influence of age and gender. J Bone Joint Surg Br 80:243-248
13. van Staa TP, Dennison EM, Leufkens HG, Cooper C 2001 Epidemiology of fractures in England and Wales. Bone 29:517-522 (Pubitemid 33124293)
14. Court-Brown CM, Caesar B 2006 Epidemiology of adult fractures: a review. Injury 37:691-697 (Pubitemid 44066989)
15. Donaldson LJ, Reckless IP, Scholes S, Mindell JS, Shelton NJ 2008 The epidemiology of fractures in England. J Epidemiol Community Health 62:174-180 (Pubitemid 351196859)
16. Johnell O, Kanis JA 2006 An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726-1733 (Pubitemid 44607392)
17. Memon A, Pospula WM, Tantawy AY, Abdul-Ghafar S, Suresh A, Al-Rowaih A 1998 Incidence of hip fracture in Kuwait. Int J Epidemiol 27:860-865 (Pubitemid 28504975)
18. Maggi S, Kelsey JL, Litvak J, Heyse SP 1991 Incidence of hip fractures in the elderly: a cross-national analysis. Osteoporos Int 1:232-241
19. Castro da Rocha FA, Ribeiro AR 2003 Low incidence of hip fractures in an equatorial area. Osteoporos Int 14:496-499 (Pubitemid 36919210)
20. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK 2002 International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 17:1237-1244 (Pubitemid 34680500)
21. Xu L, Lu A, Zhao X, Chen X, Cummings SR 1996 Very low rates of hip fracture in Beijing, People's Republic of China: the Beijing Osteoporosis Project. Am J Epidemiol 144:901-907 (Pubitemid 26374959)
22. Solomon L 1968 Osteoporosis and fracture of the femoral neck in the South African Bantu. J Bone Joint Surg Br 50:2-13
23. Krabbe S, Christiansen C, Rødbro P, Transbøl I 1980 Pubertal growth as reflected by simultaneous changes in bone mineral content and serum alkaline phosphatase. Acta Paediatr Scand 69: 49-52 (Pubitemid 10205494)
24. Seeman E 1995 The dilemma of osteoporosis in men. Am J Med 98:76S-88S
25. Bonjour JP, Theintz G, Law F, Slosman D, Rizzoli R 1994 Peak bone mass. Osteoporos Int 4(Suppl 1):7-13
26. Fatayerji D, Eastell R 1999 Age-related changes in bone turnover in men. J Bone Miner Res 14:1203-1210 (Pubitemid 29314065)
27. Khosla S, Melton 3rd LJ, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL 1998 Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogens. J Clin Endocrinol Metab 83: 2266-2274 (Pubitemid 28503012)
28. Gallagher JC, Kinyamu HK, Fowler SE, Dawson-Hughes B, Dalsky GP, Sherman SS 1998 Calciotropic hormones and bone markers in the elderly. J Bone Miner Res 13:475-482 (Pubitemid 28146230)
29. Clarke BL, Ebeling PR, Jones JD, Wahner HW, O'Fallon WM, Riggs BL, Fitzpatrick LA 2002 Predictors of bone mineral density in aging healthy men varies by skeletal site. Calcif Tissue Int 70: 137-145 (Pubitemid 36929592)
30. Binkley N, Adler RA 2010 Dual-energy x-ray absorptiometry (DXA) in men. In: Orwoll ES, Bilezikian JP, Vanderschueren D, eds. Osteoporosis in men. San Diego: Academic Press; 525-540
31. Zebaze R, Seeman E 2010 Age-related changes in bone remodeling and microarchitecture. In: Orwoll ES, Bilezikian JP, Vanderscheren D, eds. Osteoporosis in men. San Diego: Academic Press; 167-178
32. Riggs BL, Melton Iii 3rd LJ, Robb RA, Camp JJ, Atkinson EJ, Peterson JM, Rouleau PA, McCollough CH, Bouxsein ML, Khosla S 2004 Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res 19:1945-1954 (Pubitemid 41103408)
33. Szulc P 2010 Changes in bone size and geometry with aging. In: Orwoll ES, Bilezikian JP, Vanderscheren D, eds. Osteoporosis in men. San Diego: Academic Press; 193-206
34. Gennari L, Khosla S, Bilezikian JP 2008 Estrogen and fracture risk in men. J Bone Miner Res 23:1548-1551
35. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS 1994 Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N Engl J Med 331:1056-1061 (Pubitemid 24317698)
36. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER 1997 Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 337:91-95 (Pubitemid 27284394)
37. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K 1995 Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80:3689-3698
38. Bilezikian JP, Morishima A, Bell J, Grumbach MM 1998 Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 339:599-603 (Pubitemid 28385657)
39. Orwoll E, Lambert LC, Marshall LM, Blank J, Barrett-Connor E, Cauley J, Ensrud K, Cummings SR 2006 Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med 166:2124-2131 (Pubitemid 44631401)
40. Greendale GA, Edelstein S, Barrett-Connor E 1997 Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernado study. J Bone Miner Res 12:1833-1843 (Pubitemid 27500195)
41. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S 2000 Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1553-1560 (Pubitemid 32038592)
42. Fink HA, Ewing SK, Ensrud KE, Barrett-Connor E, Taylor BC, Cauley JA, Orwoll ES 2006 Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 91:3908-3915 (Pubitemid 44536863)
43. LeBlanc ES, Nielson CM, Marshall LM, Lapidus JA, Barrett-Connor E, Ensrud KE, Hoffman AR, Laughlin G, Ohlsson C, Orwoll ES 2009 The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in men. J Clin Endocrinol Metab 94:3337-3346
44. Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS 2003 Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 88:204-210 (Pubitemid 36115166)
45. Rao DS, Honasoge M 1996 Metabolic bone disease in gastrointestinal, hepatobiliary, and pancreatic disorders. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 3rd ed. New York: Lippincott-Raven; 306-310
46. Siegel LM, Bilezikian JP 1995 Metabolic bone diseases and disorders of the gastrointestinal tract. In: Singer MV, Ziegler R, eds. Gastrointestinal tract and endocrine system (Falk Symposium). Dordrecht, The Netherlands: Kluwer Academic Publishers; 113-129
47. Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA 2008 Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2003-2004. Am J Clin Nutr 88:1519-1527
48. MacLaughlin J, Holick MF 1985 Aging decreases the capacity of the human skin to produce vitamin D3. J Clin Invest 76:1536-1538 (Pubitemid 16193572)
49. Clemens TL, Zhou XY, Myles M, Endres D, Lindsay R 1986 Serum vitamin D3 and vitamin D2 concentrations and absorption of vitamin D2 in elderly subjects. J Clin Endocrinol Metab 63:656-660 (Pubitemid 16050566)
50. Ebeling PR, Sandgren ME, DiMagno EP, Lane AW, DeLuca HF, Riggs BL 1992 Evidence of an age-related decrease in intestinal responsiveness to vitamin D: relationship between serum 1,25-dihydroxyvitamin D3 and intestinal vitamin D receptor concentrations in normal women. J Clin Endocrinol Metab 75:176-182
51. Barragry JM, France MW, Corless D, Gupta SP, Switala S, Boucher BJ, Cohen RD 1978 Intestinal cholecalciferol absorption in the elderly and in young subjects. Clin Sci Mol Med 55:213-220 (Pubitemid 8386869)
52. Epstein S, Bryce G, Hinman JW, Miller ON, Riggs BL, Hui SL, Johnston Jr CC 1986 The influence of age on bone mineral regulating hormones. Bone 7:421-425 (Pubitemid 17221255)
53. Sherman SS, Hollis BW, Tobin JD 1990 Vitamin D status and related parameters in a healthy population: the effects of age, sex, and season. J Clin Endocrinol Metab 71:405-413
54. Khosla S, Melton III LJ, Riggs BL 2001 Parathyroid function in the normal aging process. In: Bilezikian JP, Marcus R, Levine MA, eds. The parathyroids. San Diego: Academic Press; 835-842
55. Ebeling PR 2008 Clinical practice. Osteoporosis in men. N Engl J Med 358:1474-1482
56. Diamond TH, Thornley SW, Sekel R, Smerdely P 1997 Hip fracture in elderly men: prognostic factors and outcomes. Med J Aust 167:412-415 (Pubitemid 27474867)
57. Wang XF, Duan Y, Beck TJ, Seeman E 2005 Varying contributions of growth and ageing to racial and sex differences in femoral neck structure and strength in old age. Bone 36:978-986 (Pubitemid 40797998)
58. Finkelstein JS, Klibanski A, Neer RM 1999 Evaluation of lumbar spine bone mineral density (BMD) using dual energy x-ray absorptiometry (DXA) in 21 young men with histories of constitutionally delayed puberty. J Clin Endocrinol Metab 84:3400-3401
59. Sattin RW, Lambert Huber DA, DeVito CA, Rodriguez JG, Ros A, Bacchelli S, Stevens JA, Waxweiler RJ 1990 The incidence of fall injury events among the elderly in a defined population. Am J Epidemiol 131:1028-1037 (Pubitemid 20178624)
60. Stevens JA, Sogolow ED 2005 Gender differences for non-fatal unintentional fall related injuries among older adults. Inj Prev 11: 115-119 (Pubitemid 40576591)
61. Liu H, Paige NM, Goldzweig CL, Wong E, Zhou A, Suttorp MJ, Munjas B, Orwoll E, Shekelle P 2008 Screening for osteoporosis in men: a systematic review for an American College of Physicians guideline. Ann Intern Med 148:685-701 (Pubitemid 351669114)
62. Papaioannou A, Kennedy CC, Cranney A, Hawker G, Brown JP, Kaiser SM, Leslie WD, O'Brien CJ, Sawka AM, Khan A, Siminoski K, Tarulli G, Webster D, McGowan J, Adachi JD 2009 Risk factors for low BMD in healthy men age 50 years or older: a systematic review. Osteoporos Int 20:507-518
63. Kanis JA, Johnell O, Oden A, De Laet C, Mellstrom D 2004 Epidemiology of osteoporosis and fracture in men. Calcif Tissue Int 75:90-99 (Pubitemid 39166208)
64. Lewis CE, Ewing SK, Taylor BC, Shikany JM, Fink HA, Ensrud KE, Barrett-Connor E, Cummings SR, Orwoll E: Osteoporotic Fractures in Men (MrOS) Study Research Group 2007 Predictors of non-spine fracture in elderly men: the MrOS Study. J Bone Miner Res 22:211-219
65. Cawthon PM, Ewing SK, McCulloch CE, Ensrud KE, Cauley JA, Cummings SR, Orwoll ES: Osteoporotic Fractures in Men (MrOS) Research Group 2009 Loss of hip BMD in older men: the osteoporotic fractures inmen(MrOS) study. J Bone Miner Res 24:1728-1735
66. Cauley JA, Fullman RL, Stone KL, Zmuda JM, Bauer DC, Barrett- Connor E, Ensrud K, Lau EM, Orwoll ES 2005 Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int 16:1525-1537
67. Mackey DC, Lui LY, Cawthon PM, Bauer DC, Nevitt MC, Cauley JA, Hillier TA, Lewis CE, Barrett-Connor E, Cummings SR 2007 High-trauma fractures and low bone mineral density in older women and men. JAMA 298:2381-2388 (Pubitemid 350190779)
68. Finkelstein JS, Klibanski A, Neer RM 1996 A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. J Clin Endocrinol Metab 81:1152-1155 (Pubitemid 26083985)
69. Szulc P, Munoz F, Duboeuf F, Marchand F, Delmas PD 2005 Bone mineral density predicts osteoporotic fractures in elderly men: the MINOS study. Osteoporos Int 16:1184-1192 (Pubitemid 41396945)
70. Orwoll ES, Bevan L, Phipps KR 2000 Determinants of bone mineral density in older men. Osteoporos Int 11:815-821 (Pubitemid 32049470)
71. Trimpou P, Landin-Wilhelmsen K, Odén A, Rosengren A, Wilhelmsen L 2010 Male risk factors for hip fracture - a 30-year follow- up study in 7,495 men. Osteoporos Int 21:409-416
72. Chiu GR, Araujo AB, Travison TG, Hall SA, McKinlay JB 2009 Relative contributions of multiple determinants to bone mineral density in men. Osteoporos Int 20:2035-2047
73. Heilberg IP, Weisinger JR 2006 Bone disease in idiopathic hypercalciuria. Curr Opin Nephrol Hypertens 15:394-402 (Pubitemid 44297982)
74. Thomas-John M, Codd MB, Manne S, Watts NB, Mongey AB 2009 Risk factors for the development of osteoporosis and osteoporotic fractures among older men. J Rheumatol 36:1947-1952
75. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E 2008 FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385-397
76. Kanis JA, McCloskey EV, Johansson H, Oden A 2010 Diagnostic thresholds for osteoporosis in men. In: Orwoll ES, Bilezikian JP, Vanderscheren D, eds. Osteoporosis in men. San Diego: Academic Press; 605-611
77. Sandhu SK, Nguyen ND, Center JR, Pocock NA, Eisman JA, Nguyen TV 2010 Prognosis of fracture: evaluation of predictive accuracy of the FRAX algorithm and Garvan nomogram. Osteoporos Int 21:863-871
78. Leslie WD, Tsang JF, Lix LM 2009 Manitoba Bone Density Program. Simplified system for absolute fracture risk assessment: clinical validation in Canadian women. J Bone Miner Res 24:353-360
79. Leslie WD, Lix LM 2010 Simplified 10-year absolute fracture risk assessment: a comparison of men and women. J Clin Densitom 13:141-146
80. Adler RA, Tran MT, Petkov VI 2003 Performance of the osteoporosis self-assessment screening tool for osteoporosis in American men. Mayo Clin Proc 78:723-727 (Pubitemid 36665903)
81. Lynn HS, Woo J, Leung PC, Barrett-Connor EL, Nevitt MC, Cauley JA, Adler RA, Orwoll ES, Osteoporotic Fractures in Men (MrOS) Study 2008 An evaluation of osteoporosis screening tools for the osteoporotic fractures inmen(MrOS) study. Osteoporos Int 19:1087-1092
82. Cummings SR, Cawthon PM, Ensrud KE, Cauley JA, Fink HA, Orwoll ES: Osteoporotic Fractures in Men (MrOS) Research Groups; Study of Osteoporotic Fractures Research Groups 2006 BMD and risk of hip and nonvertebral fracture in older men: a prospective study and comparison with olderwomen. J Bone Miner Res 21:1550-1556
83. Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, Hofman A, Uitterlinden AG, van Leeuwen JP, Pols HA 2004 Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone 34:195-202 (Pubitemid 38142449)
84. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A 2000 Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610 (Pubitemid 30659471)
85. Ringe JD, Faber H, Farahmand P, Dorst A 2006 Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 26:427-431
86. Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD 2009 Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24:719-725
87. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA 2003 The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17 (Pubitemid 36008334)
88. Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, Orwoll ES, Melton 3rd LJ, Bauer DC, Ensrud KE 2007 Cost effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 298:629-637 (Pubitemid 47236414)
89. Watts NB 1999 Understanding the Bone Mass Measurement Act. J Clin Densitom 2:211-217
90. Gärdsell P, Johnell O, Nilsson BE 1990 The predictive value of forearm bone mineral content measurements in men. Bone 11: 229-232 (Pubitemid 20318176)
91. Melton 3rd LJ, Atkinson EJ, O'Connor MK, O'Fallon WM, Riggs BL 1998 Bone density and fracture risk in men. J Bone Miner Res 13:1915-1923 (Pubitemid 28535849)
92. Wiemann LM, Vallarta-Ast N, Krueger D, Binkley N 2007 Effect of female database use for T-score derivation in men. J Clin Densitom 10:244-248 (Pubitemid 47198530)
93. Henry MJ, Pasco JA, Korn S, Gibson JE, Kotowicz MA, Nicholson GC 2010 Bone mineral density reference ranges for Australian men: Geelong Osteoporosis Study. Osteoporos Int 21:909-917
94. Bruder JM, Ma JZ, Basler JW, Welch MD 2006 Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 67:152-155 (Pubitemid 43069275)
95. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM 2002 Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87:3656-3661 (Pubitemid 34879508)
96. Adler RA, Hastings FW, Petkov VI 2010 Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX. Osteoporos Int 21:647-653
97. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C 2009 Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745-755
98. Watts NB 2004 Fundamentals and pitfalls of bone densitometry using dual-energy x-ray absorptiometry (DXA). Osteoporos Int 15:847-854 (Pubitemid 39506450)
99. Silverberg SJ, Shane E, de la Cruz L, Segre GV, Clemens TL, Bilezikian JP 1989 Abnormalities in PTH secretion and 1,25-dihydroxyvitamin D3 formation in women with osteoporosis. N Engl J Med 320:277-281 (Pubitemid 19045551)
100. Simonelli C, Adler RA, Blake GM, Caudill JP, Khan A, Leib E, Maricic M, Prior JC, Eis SR, Rosen C, Kendler DL 2008 Dualenergy x-ray absorptiometry technical issues: the 2007 ISCD official positions. J Clin Densitom 11:109-122 (Pubitemid 351618379)
101. Ryan CS, Petkov VI, Adler RA 2011 Osteoporosis in men: the value of laboratory testing. Osteoporos Int 22:1845-1853
102. Legroux-Gerot I, Catanzariti L, Marchandise X, Duquesnoy B, Cortet B 2004 Bone mineral density changes in hypercalciuric osteoporotic men treated with thiazide diuretics. Joint Bone Spine 71:51-55 (Pubitemid 38183287)
103. Schousboe JT, Vokes T, Broy SB, Ferrar L, McKiernan F, Roux C, Binkley N 2008 Vertebral fracture assessment: the 2007 ISCD official positions. J Clin Densitom 11:92-108 (Pubitemid 351602190)
104. Orwoll ES, Oviatt SK, McClung MR, Deftos LJ, Sexton G 1990 The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med 112:29-34 (Pubitemid 20026366)
105. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE 1997 Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670-676 (Pubitemid 27375473)
106. Daly RM, Brown M, Bass S, Kukuljan S, Nowson C 2006 Calcium-and vitamin D3-fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomized controlled trial. J Bone Miner Res 21:397-405
107. Daly RM, Bass S, Nowson C 2006 Long-term effects of calcium-vitamin-D3- fortified milk on bone geometry and strength in older men. Bone 39:946-953 (Pubitemid 44311709)
108. Owusu W, Willett WC, Feskanich D, Ascherio A, Spiegelman D, Colditz GA 1997 Calcium intake and the incidence of forearm and hip fractures among men. J Nutr 127:1782-1787 (Pubitemid 27386404)
109. Center JR, Bliuc D, Nguyen TV, Eisman JA 2007 Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 297:387-394 (Pubitemid 46155800)
110. Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC, Anderson FH, Cooper C, Francis RM, Donaldson C, Gillespie WJ, Robinson CM, Torgerson DJ, Wallace WA 2005 Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or Vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 365:1621-1628 (Pubitemid 40693411)
111. Fardellone P, Brazier M, Kamel S, Guéris J, Graulet AM, Liénard J, Sebert JL 1998 Biochemical effects of calcium supplementation in postmenopausal women: influence of dietary calcium intake. Am J Clin Nutr 67:1273-1278 (Pubitemid 28259518)
112. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SA, Black HR, Blanchette P, Bonds DE, Brunner RL, Brzyski RG, Caan B, Cauley JA, Chlebowski RT, Cummings SR, Granek I, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Johnson KC, Judd H, Kotchen JM, Kuller LH, Langer RD, Lasser NL, Limacher MC, Ludlam S, Manson JE, Margolis KL, McGowan J, Ockene JK, O'Sullivan MJ, Phillips L, Prentice RL, Sarto GE, Stefanick ML, Van Horn L, Wactawski- Wende J, Whitlock E, Anderson GL, Assaf AR, Barad D 2006 Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669-683
113. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA 2011 The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96:53-58
114. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR 2010 Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341:c3691
115. Wang L, Manson JE, Song Y, Sesso HD 2010 Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 152:315-323
116. Giovannucci E, Liu Y, Stampfer MJ, Willett WC 2006 A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 15:203-210 (Pubitemid 43342165)
117. Baron JA, Beach M, Wallace K, Grau MV, Sandler RS, Mandel JS, Heber D, Greenberg ER 2005 Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomarkers Prev 14:586-589 (Pubitemid 40489200)
118. Orwoll E, Nielson CM, Marshall LM, Lambert L, Holton KF, Hoffman AR, Barrett-Connor E, Shikany JM, Dam T, Cauley JA; Osteoporotic Fractures in Men (MrOS) Study Group 2009 Vitamin D deficiency in older men. J Clin Endocrinol Metab 94:1214-1222
119. Cauley JA, Parimi N, Ensrud KE, Bauer DC, Cawthon PM, Cummings SR, Hoffman AR, Shikany JM, Barrett-Connor E, Orwoll E; Osteoporotic Fractures in Men (MrOS) Research Group 2010 Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men. J Bone Miner Res 25:545-553
120. Dawson-Hughes B, Mithal A, Bonjour JP, Boonen S, Burckhardt P, Fuleihan GE, Josse RG, Lips P, Morales-Torres J, Yoshimura N 2010 IOF position statement: vitamin D recommendations for older adults. Osteoporos Int 21:1151-1154
121. Holick MF, Chen TC 2008 Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 87:1080S-1086S (Pubitemid 351549267)
122. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B 2006 Estimation of optimal serum concentration of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84:18-28 (Pubitemid 44699167)
123. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM 2011 Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96: 1911-1930
124. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC 2010 Annual high-dose oral vitamin Dand falls and fractures in older women: a randomized controlled trial. JAMA 303:1815-1822
125. Binkley N, Krueger D, Gemar D, Drezner MK 2008 Correlation among 25-hydroxy-vitamin D assays. J Clin Endocrinol Metab 93:1804-1808 (Pubitemid 351656521)
126. Carter GD, Carter R, Jones J, Berry J 2004 How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin Chem 50:2195-2197 (Pubitemid 39425873)
127. Janney CA, Cauley JA, Cawthon PM, Kriska AM 2010 Longitudinal physical activity changes in older men in the Osteoporotic Fractures in Men Study. J Am Geriatr Soc 58:1128-1133
128. de Kam D, Smulders E, Weerdesteyn V, Smits-Engelsman BC 2009 Exercise interventions to reduce fall-related fractures and their risk factors in individuals with low bone density: a systematic review of randomized controlled trials. Osteoporos Int 20:2111-2125
129. Sinaki M, Pfeifer M, Preisinger E, Itoi E, Rizzoli R, Boonen S, Geusens P, Minne HW 2010 The role of exercise in the treatment of osteoporosis. Curr Osteoporos Rep 8:138-144
130. Kukuljan S, Nowson CA, Sanders KM, Nicholson GC, Seibel MJ, Salmon J, Daly RM 2011 Independent and combined effects of calcium-vitamin D3 and exercise on bone structure and strength in older men: an 18-month factorial design randomized controlled trial. J Clin Endocrinol Metab 96:955-963
131. Smulders E, Weerdesteyn V, Groen BE, Duysens J, Eijsbouts A, Laan R, van Lankveld W 2010 Efficacy of a short multidisciplinary falls prevention program for elderly persons with osteoporosis and a fall history: a randomized controlled trial. Arch Phys Med Rehabil 91:1705-1711
132. Cawthon PM, Harrison SL, Barrett-Connor E, Fink HA, Cauley JA, Lewis CE, Orwoll ES, Cummings SR 2006 Alcohol intake and its relationship with bone mineral density, falls, and fracture risk in older men. J Am Geriatr Soc 54:1649-1657 (Pubitemid 44665202)
133. Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, Pols H, Tenenhouse A 2005 Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737-742 (Pubitemid 40933589)
134. Felson DT, Kiel DP, Anderson JJ, Kannel WB 1988 Alcohol consumption and hip fractures: the Framingham Study. Am J Epidemiol 128:1102-1110 (Pubitemid 18265394)
135. Høidrup S, Grønbaek M, Gottschau A, Lauritzen JB, Schroll M 1999 Alcohol intake, beverage preference, and risk of hip fracture in men and women. Copenhagen Centre for Prospective Population Studies. Am J Epidemiol 149:993-1001 (Pubitemid 29246863)
136. Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, Fujiwara S, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A 2005 Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:155-162 (Pubitemid 40193202)
137. Cornuz J, Feskanich D, Willett WC, Colditz GA 1999 Smoking, smoking cessation, and risk of hip fracture in women. Am J Med 106:311-314 (Pubitemid 29153409)
138. Hannan MT, Felson DT, Dawson-Hughes B, Tucker KL, Cupples LA, Wilson PW, Kiel DP 2000 Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 15:710-720 (Pubitemid 30174025)
139. Lemmens V, Oenema A, Knut IK, Brug J 2008 Effectiveness of smoking cessation interventions among adults: a systematic review of reviews. Eur J Cancer Prev 17:535-544
140. Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS 2010 Efficacy and safety of a once-yearly i.v. infusion of zolendronic acid 5mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 25:2239-2250
141. Tosteson AN, Melton 3rd LJ, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL; National Osteoporosis Foundation Guide Committee 2008 Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437-447
142. Nguyen ND, Ahlborg HG, Center JR, Eisman JA, Nguyen TV 2007 Residual lifetime risk of fractures in men and women. J Bone Miner Res 22:781-788 (Pubitemid 351339737)
143. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, McMahon M, Patkar NM, Volkmann E, Saag KG 2010 American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoidinduced osteoporosis. Arthritis Care Res (Hoboken) 62:1515-1526
144. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J 2008 Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197-213 (Pubitemid 351665507)
145. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541 (Pubitemid 26411651)
146. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340 (Pubitemid 32107641)
147. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822
148. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S 2007 Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809 (Pubitemid 350044800)
149. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226 (Pubitemid 37152031)
150. Finkelstein JS, Leder BZ, Burnett SM, Wyland JJ, Lee H, de la Paz AV, Gibson K, Neer RM 2006 Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 91:2882-2887 (Pubitemid 44271730)
151. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E 2007 Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-1491 (Pubitemid 351229318)
152. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M 2010 Atypical subtrochanteric and diaphyseal femoral fractures: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267-2294
153. Watts NB, Diab DL 2010 Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555-1565
154. Foresta C, Ruzza G, Mioni R, Meneghello A, Baccichetti C 1983 Testosterone and bone loss in Klinefelter syndrome. Horm Metab Res 15:56-57 (Pubitemid 13175046)
155. Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, Crowley Jr WF 1987 Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 106:354-461
156. Stěpán JJ, Lachman M, Zvěrina J, Pacovský V, Baylink DJ 1989 Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 69:523-527 (Pubitemid 19221221)
157. Greenspan SL, Neer RM, Ridgway EC, Klibanski A 1986 Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 104:777-782 (Pubitemid 16115040)
158. Diamond T, Stiel D, Posen S 1989 Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med 110:430-436 (Pubitemid 19088224)
159. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A 1996 Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81:4358-3465
160. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E 1997 Long term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82:2386-2390 (Pubitemid 27337844)
161. Finkelstein JS, Klibanski A, Neer RM, Doppelt SH, Rosenthal DI, Segre GV, Crowley Jr WF 1989 Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 69:776-783 (Pubitemid 19245856)
162. Greenspan SL, Oppenheim DS, Klibanski A 1989 Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 110:526-531 (Pubitemid 19097320)
163. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL 2004 Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89:503-510 (Pubitemid 38269849)
164. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM; Task Force, Endocrine Society 2010 Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 95:2536-2559
165. Christmas C, O'Connor KG, Harman SM, Tobin JD, Münzer T, Bellantoni MF, Clair CS, Pabst KM, Sorkin JD, Blackman MR 2002 Growth hormone and sex steroid effects on bone metabolism and bone mineral density in healthy agedwomenand men. J Gerontol A Biol Sci Med Sci 57:M12-M18 (Pubitemid 34074441)
166. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad Jr JG, Strom BL 1999 Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966-1972 (Pubitemid 30647018)
167. Basurto L, Zarate A, Gomez R, Vargas C, Saucedo R, Galván R 2008 Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men. Aging Male 11:140-145
168. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG 2001 Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 56:M266-M272 (Pubitemid 32381803)
169. Mellström D, Johnell O, Ljunggren O, Eriksson AL, Lorentzon M, Mallmin H, Holmberg A, Redlund-Johnell I, Orwoll E, Ohlsson C 2006 Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res 21:529-535
170. Cauley JA, Ewing SK, Taylor BC, Fink HA, Ensrud KE, Bauer DC, Barrett-Connor E, Marshall L, Orwoll ES; Osteoporotic Fractures in Men Study (MrOS) Research Group 2010 Sex steroid hormones in older men: longitudinal associations with 4.5 year change in hip bone mineral density - the Osteoporotic Fractures in Men Study. J Clin Endocrinol Metab 95:4314-4323
171. Khosla S, Melton 3rd LJ, Atkinson EJ, O'Fallon WM 2001 Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 86: 3555-3561 (Pubitemid 32755943)
172. Mellström D, Vandenput L, Mallmin H, Holmberg AH, Lorentzon M, Odén A, Johansson H, Orwoll ES, Labrie F, Karlsson MK, Ljunggren O, Ohlsson C 2008 Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 23:1552-1560
173. Finkelstein JS, Burnett-Bowie SM, Moore AF, Jones BF, Borges LF, Youngner JM, Hahn CW, Barry CV, Leder BZ 2008 Toward a physiologically-based definition of hypogonadism in men: doseresponse relationship between testosterone and bone resorption (Abstract 1102). ASBMR 30th Annual Meeting 1001-1300. J Bone Miner Res 23:S2-S85
174. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C 1999 Bone mineral density in men treated with synthetic gonadotropin- releasing hormone agonists for prostatic carcinoma. J Urol 161:1219-1222 (Pubitemid 29426121)
175. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS 2001 Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948-955
176. Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A, Greenspan SL 2001 Bone loss in men with prostate cancer treated with gonadotropin- releasing hormone agonists. J Clin Endocrinol Metab 86:2787-2791 (Pubitemid 32545740)
177. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N 2003 Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008-2012 (Pubitemid 36576705)
178. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM 2005 Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410-6417 (Pubitemid 41759293)
179. Daniell HW 1997 Osteoporosis after orchiectomy for prostate cancer. J Urol 157:439-444 (Pubitemid 27026812)
180. Dickman PW, Adolfsson J, Aström K, Steineck G 2004 Hip fractures in men with prostate cancer treated with orchiectomy. J Urol 172:2208-2212 (Pubitemid 39507493)
181. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS 2005 Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154-164 (Pubitemid 40096612)
182. Greenspan SL, Nelson JB, Trump DL, Resnick NM 2007 Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 146:416-424 (Pubitemid 351650576)
183. Smith MR, Fallon MA, Lee H, Finkelstein JS 2004 Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89:3841-3846 (Pubitemid 39071482)
184. Lin DW, Marks LS, Morton RA, Rodriguez D 2009 Positive fracture reduction trial of toremifene 80 mg in men on ADT demonstrates significant fracture risk in untreated placebo group (Abstract 639). J Urol 181:229
185. Clowes JA, Peel NF, Eastell R 2004 The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117-1123 (Pubitemid 38368399)
186. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B 2002 A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
187. Watts NB, Lewiecki EM, Bonnick SL, Laster AJ, Binkley N, Blank RD, Geusens PP, Miller PD, Petak SM, Recker RR, Saag KG, Schousboe J, Siris ES, Bilezikian JP 2009 Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res 24:1643-1646
188. Hansen KE, Swenson ED, Baltz B, Schuna AA, Jones AN, Elliott ME 2008 Adherence to alendronate in male veterans. Osteoporos Int 19:349-356 (Pubitemid 351199186)
189. Rogers A, Glover SJ, Eastell R 2009 A randomised, doubleblinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. Bone 45:1044-1052
190. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD 2004 Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7:255-261 (Pubitemid 39178892)
191. Watts NB, Geusens P, Barton IP, Felsenberg D 2005 Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 20:2097-2104 (Pubitemid 41698773)
192. Ju HS, Leung S, Brown B, Stringer MA, Leigh S, Scherrer C, Shepard K, Jenkins D, Knudsen J, Cannon R 1997 Comparison of analytical performance and biological variability of three bone resorption assays. Clin Chem 43:1570-1576 (Pubitemid 27396349)
193. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA 2011 Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22: 391-420
194. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141-151 (Pubitemid 41716229)
195. Eastell R, Krege JH, Chen P, Glass EV, Reginster JY 2006 Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22:61-66 (Pubitemid 43106908)
196. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18: 1051-1056 (Pubitemid 37294942)
197. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD 2004 Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture. J Bone Miner Res 19:394-401 (Pubitemid 38787394)
198. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J 2004 Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344-351 (Pubitemid 38177616)
199. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronatetreated women: the fracture intervention trial. J Bone Miner Res 19:1250-1258 (Pubitemid 41094365)
200. Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, Kendler D, Eriksen EF, Mesenbrink PG, Eastell R 2009 Effects of yearly zoledronic acid 5mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res 24:1544-1551
201. Eastell R, Vrijens B, Cahall DL, Ringe JD, Garnero P, Watts NB 2011 Bone turnover markers and bone mineral density response with risedronate therapy relationship with fracture risk and patient adherence. J Bone Miner Res 26:1662-1669
202. Holt G, Smith R, Duncan K, Hutchison JD, Gregori A 2008 Gender differences in epidemiology and outcome after hip fracture: evidence from the Scottish Hip Fracture Audit. J Bone Joint Surg 90B:480-483 (Pubitemid 351542866)
203. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gomez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C 2012 Denosumab and bone-metastasis- free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379:39-46